Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VELTASSA vs SPS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
VELTASSA (patiromer) is a non-absorbed polymer that binds potassium ions in the gastrointestinal tract, reducing serum potassium levels by increasing fecal potassium excretion.
SPS (sodium polystyrene sulfonate) is a cation-exchange resin that exchanges sodium ions for potassium ions in the gastrointestinal tract, primarily in the colon, thereby reducing serum potassium levels.
Treatment of hyperkalemia,Off-label: Management of hyperkalemia in patients on renin-angiotensin-aldosterone system inhibitors
Treatment of hyperkalemia
8.4 g (1 packet) orally once daily; titrate to a maximum of 25.2 g (3 packets) once daily as needed to achieve normokalemia.
15-60 g orally 1-4 times daily; administer as a suspension in water or juice. Alternatively, 30-50 g rectally as a retention enema every 6 hours.
Not applicable due to non-systemic action; patiromer acts locally in the gastrointestinal tract and is not absorbed. Elimination half-life of the polymer is not measurable clinically.
Not applicable; SPS acts locally in the gastrointestinal tract and does not undergo systemic absorption. No terminal half-life can be defined.
Not metabolized; eliminated unchanged in feces.
SPS is not absorbed systemically and is excreted unchanged in the feces.
Primarily eliminated via feces as insoluble, non-absorbed polymer (80-90%); minimal renal excretion (<0.01% of administered dose as intact drug in urine), biliary excretion negligible.
SPS (sodium polystyrene sulfonate) is a cation-exchange resin that is not absorbed systemically. It is excreted entirely in the feces, with no renal or biliary elimination. The resin-bound potassium is eliminated via the gastrointestinal tract.
Not absorbed, therefore protein binding is not applicable; the drug is not systemically available.
Not applicable; SPS is not absorbed and does not bind to plasma proteins.
Not applicable (non-systemic); Vd cannot be measured as the drug is not absorbed into systemic circulation.
Not applicable; SPS remains within the gastrointestinal lumen and does not distribute into body tissues. Reported Vd is negligible.
Negligible (<0.01%) after oral administration; patiromer acts locally and is not absorbed due to high molecular weight and non-digestible polymer structure.
Oral: 0% (not absorbed); rectal: 0% (not absorbed). SPS acts locally without systemic availability.
No dose adjustment is required for mild to moderate renal impairment (e GFR 30-89 m L/min/1.73 m²). For severe renal impairment (e GFR <30 m L/min/1.73 m²) or dialysis-dependent patients, use with caution; starting dose 8.4 g once daily with close monitoring of serum potassium.
No specific dose adjustment is recommended based on GFR. Use with caution in patients with renal impairment due to risk of electrolyte disturbances (e.g., hypernatremia, hypokalemia).
No specific dose adjustment recommended for Child-Pugh Class A or B. For Child-Pugh Class C (severe hepatic impairment), use with caution due to lack of data; no dose adjustment proposed.
No dose adjustment required for hepatic impairment. Monitor serum electrolytes and fluid balance in patients with hepatic disease.
Safety and efficacy have not been established in pediatric patients (age <18 years). No recommended dosing.
Children (2-12 years): 0.5-2 g/kg/day divided every 4-6 hours; maximum 30 g/day. Administer orally or rectally as per adult guidance.
No specific dose adjustment required. Elderly patients may have decreased renal function; monitor serum potassium and renal function periodically.
Use lowest effective dose; monitor electrolyte levels and renal function more frequently due to age-related decline in renal function and increased risk of electrolyte imbalance.
None
No FDA black box warning.
Bowel obstruction or perforation risk in patients with gastrointestinal disorders,Severe constipation,Hypomagnesemia,Increased risk of gastrointestinal adverse events when used with certain drugs
Risk of intestinal necrosis, particularly with concomitant use of sorbitol,Electrolyte disturbances (e.g., hypokalemia, hypocalcemia, hypernatremia),Use with caution in patients with gastrointestinal disorders or postoperative patients
Known hypersensitivity to patiromer,Severe constipation,Obstructive bowel disorders,Ileus or bowel perforation
Hypokalemia,Obstructive bowel disease,Neonates with reduced gut motility (postoperative or drug-induced),Concurrent use with sorbitol
Take with food to improve tolerability. No specific dietary restrictions beyond standard potassium management. Avoid high-potassium foods if directed by physician.
Avoid high-potassium foods such as bananas, oranges, tomatoes, potatoes, and spinach to prevent excessive potassium intake. SPS may bind to some foods, but no specific food restrictions beyond potassium-rich foods are required. Do not mix SPS with fruit juices; use only water or simple syrup.
FDA Pregnancy Category C. In animal reproduction studies, patiromer administered to pregnant rats and rabbits at doses up to 10 times the human clinical dose (6.3 g/day) showed no evidence of fetal harm. However, no adequate and well-controlled studies in pregnant women. Potential risks: maternal electrolyte disturbances (e.g., hypokalemia, hypomagnesemia) may pose fetal risk; use only if clearly needed.
SPS (sodium polystyrene sulfonate) is not absorbed systemically; therefore, no direct fetal risk is expected. However, electrolyte disturbances (e.g., hypokalemia, hypocalcemia) from maternal use could indirectly affect the fetus. First trimester: No known teratogenic effects. Second/Third trimester: Risk of maternal electrolyte imbalance may impact fetal development. Use only if clearly needed.
No data on presence in human milk, effects on breastfed infant, or milk production. Patiromer is a non-absorbed polymer; systemic absorption is negligible (<0.001%), so minimal excretion into breast milk is expected. Caution advised; consider developmental and health benefits of breastfeeding along with mother's clinical need.
Excretion into breast milk is unlikely due to non-absorbable nature. M/P ratio not applicable. Considered compatible with breastfeeding, but monitor infant for electrolyte disturbances if maternal use is prolonged.
No specific dose adjustments recommended based on pharmacokinetic changes in pregnancy. Patiromer is not systemically absorbed; pregnancy-induced changes in GI motility or transit time are unlikely to affect efficacy. Dose should be guided by serum potassium levels, with caution due to potential electrolyte disturbances.
No pharmacokinetic changes expected due to lack of absorption. Standard dosing may be used, but monitor electrolytes frequently due to altered renal function and volume of distribution in pregnancy. Dose adjustments are not required, but lower doses may suffice to avoid severe electrolyte shifts.
VELTASSA (patiromer) is a non-absorbed potassium-binding polymer used for hyperkalemia. Administer at least 3 hours apart from other oral medications due to binding risk. Monitor serum potassium periodically; reduce dose or discontinue if hypokalemia occurs. Not for emergency treatment of life-threatening hyperkalemia due to slow onset. Avoid in patients with bowel obstruction or severe constipation.
SPS (sodium polystyrene sulfonate) is a potassium-lowering resin that exchanges sodium for potassium in the GI tract. Administer orally or as a retention enema. Monitor for hypokalemia, hypomagnesemia, and sodium overload. Contraindicated in patients with bowel obstruction, severe constipation, or postoperative ileus due to risk of intestinal necrosis. Use with caution in patients on NSAIDs or with risk of colonic necrosis. Do not mix with sorbitol; use of sorbitol increases risk of intestinal necrosis. Monitor serum potassium levels frequently.
Take exactly as prescribed, usually once daily with food.,Separate from other oral medications by at least 3 hours.,Mix powder with water (approximately 120 m L) and stir; drink immediately.,Do not heat or add to hot foods/liquids.,Contact doctor if experiencing constipation, severe stomach pain, or signs of low potassium (muscle cramps, weakness, irregular heartbeat).,Keep medication at room temperature; do not freeze.
Take this medication exactly as prescribed, usually 1 to 4 times a day.,Do not mix SPS with orange juice or other fruit juices; it should be mixed with water or syrup.,This medication may cause constipation, so drink plenty of fluids and eat high-fiber foods.,If you experience severe constipation, severe abdominal pain, vomiting, or blood in vomit or stool, seek medical attention immediately.,Avoid taking other medications within 3 hours of SPS as it may bind to them and reduce their effectiveness.,Inform your doctor if you have a history of bowel obstruction, constipation, or kidney disease.,Do not use sorbitol or other laxatives with SPS unless directed by your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VELTASSA vs SPS, answered by our medical review team.
VELTASSA is a Potassium Binder that works by VELTASSA (patiromer) is a non-absorbed polymer that binds potassium ions in the gastrointestinal tract, reducing serum potassium levels by increasing fecal potassium excretion.. SPS is a Potassium Binder that works by SPS (sodium polystyrene sulfonate) is a cation-exchange resin that exchanges sodium ions for potassium ions in the gastrointestinal tract, primarily in the colon, thereby reducing serum potassium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VELTASSA and SPS depend on the specific clinical indication. These are both Potassium Binder agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VELTASSA is: 8.4 g (1 packet) orally once daily; titrate to a maximum of 25.2 g (3 packets) once daily as needed to achieve normokalemia.. The standard adult dose of SPS is: 15-60 g orally 1-4 times daily; administer as a suspension in water or juice. Alternatively, 30-50 g rectally as a retention enema every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VELTASSA and SPS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VELTASSA is classified as Category C. FDA Pregnancy Category C. In animal reproduction studies, patiromer administered to pregnant rats and rabbits at doses up to 10 times the human clinical dose (6.3 g/day) showed no . SPS is classified as Category C. SPS (sodium polystyrene sulfonate) is not absorbed systemically; therefore, no direct fetal risk is expected. However, electrolyte disturbances (e.g., hypokalemia, hypocalcemia) fr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.